Get the Stockscreener App
10.84
0.09%
0.06
After Hours:
10.85
0.010
+0.09%
Celcuity Inc stock is traded at $10.84, with a volume of 106.34K.
It is up +0.09% in the last 24 hours and up +26.13% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$10.90
Open:
$10.82
24h Volume:
106.34K
Relative Volume:
0.40
Market Cap:
$419.64M
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-4.0448
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
-1.62%
1M Performance:
+26.13%
6M Performance:
-28.37%
1Y Performance:
-38.26%
1-Day Range:
$10.49
$11.15
1-Week Range:
$10.49
$11.66
52-Week Range:
$7.575
$19.77
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
10.85 | 419.64M | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.76 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.40 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.58 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.84 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.68 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
JPMorgan Chase & Co. Has $192,000 Stake in Celcuity Inc. (NASDAQ:CELC) - Defense World
Q1 Earnings Estimate for Celcuity Issued By Leerink Partnrs - Defense World
When (CELC) Moves Investors should Listen - news.stocktradersdaily.com
Brokerages Set Celcuity Inc. (NASDAQ:CELC) Price Target at $30.17 - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates - ACCESS Newswire
Geode Capital Management LLC Acquires 62,003 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionCelcuity (NASDAQ:CELC), Five Point Hldgs (NYSE:FPH) - Benzinga
Is Celcuity (NASDAQ:CELC) Using Debt Sensibly? - simplywall.st
Celcuity Inc. (NASDAQ:CELC) Stock Holdings Lifted by Vanguard Group Inc. - Defense World
Where are the Opportunities in (CELC) - news.stocktradersdaily.com
Celcuity Inc. (NASDAQ:CELC) Shares Purchased by Wellington Management Group LLP - Defense World
Corebridge Financial Inc. Has $213,000 Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
Needham & Company LLC Reiterates “Buy” Rating for Celcuity (NASDAQ:CELC) - Defense World
Celcuity at Needham Conference: New Frontiers in Cancer Treatment By Investing.com - Investing.com Canada
Celcuity at Stifel Forum: Insights on Cancer Drug Trials By Investing.com - Investing.com Canada
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Celcuity projects $2B revenue potential for gedatolisib in second-line breast cancer market - MSN
What is HC Wainwright’s Forecast for Celcuity Q1 Earnings? - The AM Reporter
Celcuity Stock Hits 52-Week Low at $8.46 Amid Market Challenges - Investing.com Australia
Celcuity Stock Hits 52-Week Low at $8.46 Amid Market Challenges By Investing.com - Investing.com South Africa
Research Analysts Offer Predictions for Celcuity Q1 Earnings - Defense World
Celcuity Announces Closing of Common Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock - ACCESS Newswire
Celcuity (NASDAQ:CELC) Receives Buy Rating from Needham & Company LLC - Defense World
Celcuity (NASDAQ:CELC) Given Buy Rating at HC Wainwright - Defense World
Brokerages Set Celcuity Inc. (NASDAQ:CELC) PT at $30.17 - Defense World
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - ACCESS Newswire
Celcuity Stock (CELC) Dips Despite Promising Cancer Treatment in Pipeline - The Globe and Mail
Celcuity Inc. Earnings Call Highlights Progress and Challenges - TipRanks
Stifel maintains Celcuity stock Buy rating, $42 target By Investing.com - Investing.com Canada
Celcuity Inc (NASDAQ:CELC) Misses Earning Expectations - FXDailyReport.Com
Stifel maintains Celcuity stock Buy rating, $42 target - Investing.com
Celcuity Inc. (NASDAQ:CELC) Q4 2024 Earnings Call Transcript - Insider Monkey
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences - GlobeNewswire
Celcuity Inc. Reports 2024 Financial Results and Clinical Updates - TipRanks
Earnings call transcript: Celcuity Q4 2024 reveals wider losses By Investing.com - Investing.com Canada
Celcuity Inc. SEC 10-K Report - TradingView
Celcuity Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CELCUITY Earnings Results: $CELC Reports Quarterly Earnings - Nasdaq
Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
Earnings Scheduled For March 31, 2025 - Benzinga
(CELC) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Has $3.11 Million Stock Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
Bank of New York Mellon Corp Buys 10,828 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call - GlobeNewswire
Celcuity (CELC) Projected to Post Quarterly Earnings on Wednesday - Defense World
Celcuity at Leerink Global Healthcare Conference: Promising Cancer Drug Insights By Investing.com - Investing.com South Africa
Celcuity at Leerink Global Healthcare Conference: Promising Cancer Drug Insights - Investing.com Canada
BlackRock, Inc. Expands Holdings with Celcuity Inc. Acquisition - GuruFocus
Rhumbline Advisers Boosts Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
(CELC) Technical Data - Stock Traders Daily
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):